Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Rae

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Plos One|November 15, 2021
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancerElizabeth P Darga, Emily M Dolce, Fang Fang, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 17, 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)Mattias Bergqvist, Adrian Nordmark, Amy Williams, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECTJune M Chan, Amy K Darke, Kathryn L Penney, et al.
Cancer Research Communications|November 16, 2022
Bcl-xL inhibition radiosensitizes <i>PIK3CA/PTEN</i> wild-type triple negative breast cancers with low Mcl-1 expressionAndrea M Pesch, Benjamin C Chandler, Anna R Michmerhuizen, et al.
Breast Cancer Research and Treatment|April 3, 2013
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN Lynn Henry, Todd C Skaar, Jessica Dantzer, et al.
The Oncologist|March 25, 2016
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast CancerKunal C Kadakia, Claire F Snyder, Kelley M Kidwell, et al.
Cancer Medicine|June 20, 2024
Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advancesAlex K Bryant, Rafael Zamora-Resendiz, Xin Dai, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Plos One|November 15, 2021
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancerElizabeth P Darga, Emily M Dolce, Fang Fang, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 17, 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)Mattias Bergqvist, Adrian Nordmark, Amy Williams, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECTJune M Chan, Amy K Darke, Kathryn L Penney, et al.
Cancer Research Communications|November 16, 2022
Bcl-xL inhibition radiosensitizes <i>PIK3CA/PTEN</i> wild-type triple negative breast cancers with low Mcl-1 expressionAndrea M Pesch, Benjamin C Chandler, Anna R Michmerhuizen, et al.
Breast Cancer Research and Treatment|April 3, 2013
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN Lynn Henry, Todd C Skaar, Jessica Dantzer, et al.
The Oncologist|March 25, 2016
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast CancerKunal C Kadakia, Claire F Snyder, Kelley M Kidwell, et al.
Cancer Medicine|June 20, 2024
Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advancesAlex K Bryant, Rafael Zamora-Resendiz, Xin Dai, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Pageof 13